Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-24-000123
Filing Date
2024-09-13
Accepted
2024-09-13 18:26:34
Documents
1
Period of Report
2024-09-11

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1726266388.html 4  
1 FORM 4 wk-form4_1726266388.xml 4 5105
  Complete submission text file 0001610618-24-000123.txt   6715
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O CIDARA THERAPEUTICS, INC. 6310 NANCY RIDGE DR SUITE 101 SAN DIEGO CA 92121
Business Address
Tari Leslie (Reporting) CIK: 0001870270 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 241298953